Synopsis
Synopsis
0
VMF
0
Australia
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Anhydrous, Ciprofloxacin Hydrochloride
2. Bay 09867
3. Bay-09867
4. Bay09867
5. Ciprinol
6. Cipro
7. Ciprofloxacin
8. Ciprofloxacin Hydrochloride Anhydrous
9. Ciprofloxacin Monohydrochloride Monohydrate
10. Hydrochloride Anhydrous, Ciprofloxacin
11. Hydrochloride, Ciprofloxacin
12. Monohydrate, Ciprofloxacin Monohydrochloride
13. Monohydrochloride Monohydrate, Ciprofloxacin
1. Ciprofloxacin Hcl
2. 93107-08-5
3. 86483-48-9
4. 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic Acid Hydrochloride
5. Cipro
6. Chebi:310388
7. Ciprofloxacin Hydrochloride Anhydrous
8. 0mp32mfp6c
9. 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic Acid Hydrochloride
10. Ciprofloxacin (monohydrochloride)
11. Bay-o-9867
12. Ciprofloxacin Hydrochloride (anh.)
13. Bay O 9867
14. Cetraxal
15. Ciprobay
16. Ciproxan
17. Ciproxin
18. Flociprin
19. Ciflox
20. Mfcd00079044
21. 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic Acid Hcl
22. 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic Acid;hydrochloride
23. 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic Acid Xhydrochloride
24. Bay-o 9867
25. 93107-08-5 (hcl)
26. 1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic Acid Hydrochloride
27. Dsstox_cid_27768
28. Dsstox_rid_82545
29. Dsstox_gsid_47788
30. Ciprofloxacin (as Hydrochloride)
31. Prestwick_67
32. 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic Acid; Hydrochloride
33. 4-(3-carboxy-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinolin-7-yl)-piperazin-1-ium; Chloride
34. Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic Acid, Monohydrochloride
35. Nsc620634
36. Ciprofloxacin Hydrochloride (anhydrous)
37. Ciprofloxacin 100 Microg/ml In Methanol
38. Ncgc00016959-01
39. Cas-93107-08-5
40. Unii-0mp32mfp6c
41. 3-quinolinecarboxylic Acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, Hydrochloride
42. 3-quiolinecarboxylic Acid
43. Ciprofloxacine Hydrochloride
44. Epitope Id:174846
45. Cambridge Id 5807784
46. Ciprofloxacini Hydrochloridum
47. Chembl1202
48. Schembl42310
49. 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic Acid Monohydrochloride
50. 3-quinolinecarboxylic Acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, Monohydrochloride
51. Ciprofloxacin Hcl/lactate
52. Dtxsid1047788
53. Hy-b0356a
54. Ciprofloxacin Hydrochloride (1:x)
55. Hms1568g08
56. Bcp13634
57. Bcp14336
58. Tox21_110712
59. S5008
60. Akos005111008
61. Tox21_110712_1
62. Cs-8134
63. Ks-5012
64. Nsc-620634
65. Sb73037
66. Ncgc00016959-06
67. 3-quinolinecarboxylic Acid, 1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-, Hydrochloride
68. Ac-23972
69. Bim-0048462.p001
70. Ciprofloxacin 1000 Microg/ml In Methanol
71. Ciprofloxacin Hydrochloride [who-dd]
72. Ft-0623850
73. Ft-0623851
74. A16969
75. H10663
76. A859872
77. Q-200860
78. Q27105154
79. F0001-2378
80. Cpx; Cetraxal; Ciloxan; Cipro; Bay-09867 Hydrochloride
81. 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic Acid Hcl
82. 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylicacidxhydrochloride
83. 3-quinolinecarboxylic Acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, Hydrochloride (1:1)
Molecular Weight | 367.8 g/mol |
---|---|
Molecular Formula | C17H19ClFN3O3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 3 |
Exact Mass | 367.1098973 g/mol |
Monoisotopic Mass | 367.1098973 g/mol |
Topological Polar Surface Area | 72.9 Ų |
Heavy Atom Count | 25 |
Formal Charge | 0 |
Complexity | 571 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Ciprofloxacin hydrochloride |
PubMed Health | Ciprofloxacin Betaine/Ciprofloxacin Hydrochloride (By mouth) |
Drug Classes | Antibacterial |
Drug Label | Ciprofloxacin Tablets, USPis a synthetic broad spectrum antimicrobial agent for oral administration. Ciprofloxacin hydrochloride, USP, a fluoroquinolone, is the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-pip... |
Active Ingredient | Ciprofloxacin hydrochloride |
Dosage Form | Solution/drops; Tablet |
Route | Ophthalmic; Oral |
Strength | eq 100mg base; eq 750mg base; eq 500mg base; eq 0.3% base; eq 250mg base |
Market Status | Prescription |
Company | Watson Labs; Nexus Pharms; Ranbaxy; Ivax Sub Teva Pharms; Apotex; Bausch And Lomb; Aurobindo Pharma; Taro; Dr Reddys Labs; Unique Pharm Labs; Carlsbad; Pharmaforce; Fdc; Mylan; Hikma; Akorn |
2 of 2 | |
---|---|
Drug Name | Ciprofloxacin hydrochloride |
PubMed Health | Ciprofloxacin Betaine/Ciprofloxacin Hydrochloride (By mouth) |
Drug Classes | Antibacterial |
Drug Label | Ciprofloxacin Tablets, USPis a synthetic broad spectrum antimicrobial agent for oral administration. Ciprofloxacin hydrochloride, USP, a fluoroquinolone, is the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-pip... |
Active Ingredient | Ciprofloxacin hydrochloride |
Dosage Form | Solution/drops; Tablet |
Route | Ophthalmic; Oral |
Strength | eq 100mg base; eq 750mg base; eq 500mg base; eq 0.3% base; eq 250mg base |
Market Status | Prescription |
Company | Watson Labs; Nexus Pharms; Ranbaxy; Ivax Sub Teva Pharms; Apotex; Bausch And Lomb; Aurobindo Pharma; Taro; Dr Reddys Labs; Unique Pharm Labs; Carlsbad; Pharmaforce; Fdc; Mylan; Hikma; Akorn |
Treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
Cytochrome P-450 CYP1A2 Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP1A2. (See all compounds classified as Cytochrome P-450 CYP1A2 Inhibitors.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
65
PharmaCompass offers a list of Ciprofloxacin Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ciprofloxacin Hydrochloride manufacturer or Ciprofloxacin Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ciprofloxacin Hydrochloride manufacturer or Ciprofloxacin Hydrochloride supplier.
PharmaCompass also assists you with knowing the Ciprofloxacin Hydrochloride API Price utilized in the formulation of products. Ciprofloxacin Hydrochloride API Price is not always fixed or binding as the Ciprofloxacin Hydrochloride Price is obtained through a variety of data sources. The Ciprofloxacin Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ciprofloxacin Hydrochloride Anhydrous manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ciprofloxacin Hydrochloride Anhydrous, including repackagers and relabelers. The FDA regulates Ciprofloxacin Hydrochloride Anhydrous manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ciprofloxacin Hydrochloride Anhydrous API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ciprofloxacin Hydrochloride Anhydrous manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ciprofloxacin Hydrochloride Anhydrous supplier is an individual or a company that provides Ciprofloxacin Hydrochloride Anhydrous active pharmaceutical ingredient (API) or Ciprofloxacin Hydrochloride Anhydrous finished formulations upon request. The Ciprofloxacin Hydrochloride Anhydrous suppliers may include Ciprofloxacin Hydrochloride Anhydrous API manufacturers, exporters, distributors and traders.
click here to find a list of Ciprofloxacin Hydrochloride Anhydrous suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ciprofloxacin Hydrochloride Anhydrous DMF (Drug Master File) is a document detailing the whole manufacturing process of Ciprofloxacin Hydrochloride Anhydrous active pharmaceutical ingredient (API) in detail. Different forms of Ciprofloxacin Hydrochloride Anhydrous DMFs exist exist since differing nations have different regulations, such as Ciprofloxacin Hydrochloride Anhydrous USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ciprofloxacin Hydrochloride Anhydrous DMF submitted to regulatory agencies in the US is known as a USDMF. Ciprofloxacin Hydrochloride Anhydrous USDMF includes data on Ciprofloxacin Hydrochloride Anhydrous's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ciprofloxacin Hydrochloride Anhydrous USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ciprofloxacin Hydrochloride Anhydrous suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ciprofloxacin Hydrochloride Anhydrous Drug Master File in Japan (Ciprofloxacin Hydrochloride Anhydrous JDMF) empowers Ciprofloxacin Hydrochloride Anhydrous API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ciprofloxacin Hydrochloride Anhydrous JDMF during the approval evaluation for pharmaceutical products. At the time of Ciprofloxacin Hydrochloride Anhydrous JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ciprofloxacin Hydrochloride Anhydrous suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ciprofloxacin Hydrochloride Anhydrous Drug Master File in Korea (Ciprofloxacin Hydrochloride Anhydrous KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ciprofloxacin Hydrochloride Anhydrous. The MFDS reviews the Ciprofloxacin Hydrochloride Anhydrous KDMF as part of the drug registration process and uses the information provided in the Ciprofloxacin Hydrochloride Anhydrous KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ciprofloxacin Hydrochloride Anhydrous KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ciprofloxacin Hydrochloride Anhydrous API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ciprofloxacin Hydrochloride Anhydrous suppliers with KDMF on PharmaCompass.
A Ciprofloxacin Hydrochloride Anhydrous CEP of the European Pharmacopoeia monograph is often referred to as a Ciprofloxacin Hydrochloride Anhydrous Certificate of Suitability (COS). The purpose of a Ciprofloxacin Hydrochloride Anhydrous CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ciprofloxacin Hydrochloride Anhydrous EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ciprofloxacin Hydrochloride Anhydrous to their clients by showing that a Ciprofloxacin Hydrochloride Anhydrous CEP has been issued for it. The manufacturer submits a Ciprofloxacin Hydrochloride Anhydrous CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ciprofloxacin Hydrochloride Anhydrous CEP holder for the record. Additionally, the data presented in the Ciprofloxacin Hydrochloride Anhydrous CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ciprofloxacin Hydrochloride Anhydrous DMF.
A Ciprofloxacin Hydrochloride Anhydrous CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ciprofloxacin Hydrochloride Anhydrous CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Ciprofloxacin Hydrochloride Anhydrous suppliers with CEP (COS) on PharmaCompass.
A Ciprofloxacin Hydrochloride Anhydrous written confirmation (Ciprofloxacin Hydrochloride Anhydrous WC) is an official document issued by a regulatory agency to a Ciprofloxacin Hydrochloride Anhydrous manufacturer, verifying that the manufacturing facility of a Ciprofloxacin Hydrochloride Anhydrous active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ciprofloxacin Hydrochloride Anhydrous APIs or Ciprofloxacin Hydrochloride Anhydrous finished pharmaceutical products to another nation, regulatory agencies frequently require a Ciprofloxacin Hydrochloride Anhydrous WC (written confirmation) as part of the regulatory process.
click here to find a list of Ciprofloxacin Hydrochloride Anhydrous suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ciprofloxacin Hydrochloride Anhydrous as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ciprofloxacin Hydrochloride Anhydrous API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ciprofloxacin Hydrochloride Anhydrous as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ciprofloxacin Hydrochloride Anhydrous and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ciprofloxacin Hydrochloride Anhydrous NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ciprofloxacin Hydrochloride Anhydrous suppliers with NDC on PharmaCompass.
Ciprofloxacin Hydrochloride Anhydrous Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ciprofloxacin Hydrochloride Anhydrous GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ciprofloxacin Hydrochloride Anhydrous GMP manufacturer or Ciprofloxacin Hydrochloride Anhydrous GMP API supplier for your needs.
A Ciprofloxacin Hydrochloride Anhydrous CoA (Certificate of Analysis) is a formal document that attests to Ciprofloxacin Hydrochloride Anhydrous's compliance with Ciprofloxacin Hydrochloride Anhydrous specifications and serves as a tool for batch-level quality control.
Ciprofloxacin Hydrochloride Anhydrous CoA mostly includes findings from lab analyses of a specific batch. For each Ciprofloxacin Hydrochloride Anhydrous CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ciprofloxacin Hydrochloride Anhydrous may be tested according to a variety of international standards, such as European Pharmacopoeia (Ciprofloxacin Hydrochloride Anhydrous EP), Ciprofloxacin Hydrochloride Anhydrous JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ciprofloxacin Hydrochloride Anhydrous USP).